EUVIMEDEUVIMED entdecken
FallberichtKlinische StudieOpen Access · CC BY-NC 3.0

Vonoprazan–Amoxicillin Dual Therapy with or Without Saccharomyces boulardii Supplementation as a Rescue Regimen for Helicobacter pylori Infection

Ding-Ni Qu iD, Ze-Xuan Ji iD, Jun-Qi Zhang iD, Xiao-Yong Wang iD

Infection and Drug Resistance · 2026-04 · Volume 19 · 1-10

DOI: 10.2147/idr.s594118 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Infection and Drug Resistance, 2026-04. Verfasst von Ding-Ni Qu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, the Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, Ji…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether the incorporation of Saccharomyces boulardii (S. boulardii) into vonoprazan-amoxicillin dual therapy contributes to improved eradication rate and a lower frequency of adverse events in rescue regimens for Helicobacter pylori (H. pylori) infection has yet to be established.

Methods

In a single-center, randomized controlled trial, 190 adults with previous H. pylori treatment failure were assigned to receive either vonoprazan (20 mg twice daily) plus amoxicillin (750 mg three times daily) (VA group) or the same regimen with S. boulardii (250 mg twice daily) (VAS group) for 14 days. Eradication rates, compliance, adverse events, and safety were assessed. Risk factors influencing the eradication rate were explored.

Results

Based on intention-to-treat analysis, H. pylori eradication rates were 80.0% in the VA group and 92.6% in the VAS group (P = 0.011), and per-protocol analysis yielded eradication rates of 85.4% and 94.6%, respectively (P = 0.037). There were no significant differences in eradication rates for either the VA regimen (P = 0.736) or the VAS regimen (P = 0.431) based on the number of previous treatment failures. However, a history of prior furazolidone use reduced the eradication rate of VAS therapy. The incidence of adverse events was significantly lower in the VAS group (11.6%) than it was in the VA group (32.6%; P < 0.001). Both groups showed similar good compliance and safety.

Conclusion

Supplementing vonoprazan-amoxicillin dual therapy with S. boulardii significantly increases H. pylori eradication rates and reduces adverse events, offering an effective and simple rescue treatment unaffected by previous treatment failures. Trial Registration: Chinese Clinical Trial Registry No. ChiCTR2300075382, September 4, 2023.

Schlagwörter

Stichwörter der Autor:innen

Helicobacter pyloriSaccharomyces boulardiiamoxicillinrescue treatmentvonoprazan

Autor:innen und Institutionen

  • Department of Gastroenterology, the Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu Province, People's Republic of China.
  • Department of Pathology, the Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu Province, People's Republic of China.

ORCID-Profile: Ding-Ni Qu, Ze-Xuan Ji, Jun-Qi Zhang, Xiao-Yong Wang

Zitieren

APA

Qu, D. N., Ji, Z. X., Zhang, J. Q., & Wang, X. Y. (2026). Vonoprazan–Amoxicillin Dual Therapy with or Without Saccharomyces boulardii Supplementation as a Rescue Regimen for Helicobacter pylori Infection. Infection and Drug Resistance, Volume 19, 1-10. https://doi.org/10.2147/idr.s594118

Vancouver

Qu DN, Ji ZX, Zhang JQ, Wang XY. Vonoprazan–Amoxicillin Dual Therapy with or Without Saccharomyces boulardii Supplementation as a Rescue Regimen for Helicobacter pylori Infection. Infection and Drug Resistance. 2026;Volume 19:1-10. doi:10.2147/idr.s594118

BibTeX
@article{Qu2026,
  author = {Qu, Ding-Ni and Ji, Ze-Xuan and Zhang, Jun-Qi and Wang, Xiao-Yong},
  title = {Vonoprazan–Amoxicillin Dual Therapy with or Without Saccharomyces boulardii Supplementation as a Rescue Regimen for Helicobacter pylori Infection},
  journal = {Infection and Drug Resistance},
  year = {2026},
  volume = {Volume 19},
  pages = {1--10},
  doi = {10.2147/idr.s594118}
}
Kostenlos starten →